Summary of Use during Lactation

No information is available on the use of selpercatinib during breastfeeding. Because selpercatinib is 97% bound to plasma proteins, the amounts in milk are likely to be low. However, the manufacturer recommends that mothers should not breastfeed during treatment with selpercatinib and for 1 week after the final dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Name

Selpercatinib

CAS Registry Number

2152628-33-4

Drug Class

Breast Feeding

Lactation

Antineoplastic Agents

Enzyme Inhibitors

Protein Kinase Inhibitors

Signal Transduction Inhibitors

Tyrosine Kinase Inhibitors